The Patent Finder

Salix Pharmaceuticals, Inc.

50 patents currently held · Updated Nov 16, 2026
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

36
Ending by 2030
Sep 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 11, 2026
    The maintenance fee for Methods of Treating Hepatic Encephalopathy (US 10,314,828) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
  • 1 fee due Jan 2, 2027
    The maintenance fee for Methods of Treating Hepatic Encephalopathy (US 10,335,397) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
  • 1 fee due Mar 15, 2027
    The maintenance fee for Forms of Rifaximin and Uses Thereof (US 9,133,217) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
  • 2 fees due Apr 10 to 29, 2027 · next Apr 10
  • 1 fee due Jun 3, 2027
    The maintenance fee for Ibs Microbiota and Uses Thereof (US 10,493,064) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
  • 2 fees due Sep 1, 2027

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 18, 2026
  • 4 terms have ended since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,709,634Amorphous Form of Rifaximin and Processes for Its Preparation
In force
 · High confidence
In forceHigh confidence
US 9,273,063Method for Preparing a Rifaximin Product
In force
 · Medium confidence
In forceMedium confidence
US 7,687,075Colonic Purgative Composition with Soluble Binding Agent
In force
 · High confidence
In forceHigh confidence
US 8,067,429Forms of Rifaximin and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 8,569,326Forms of Rifaximin and Uses Thereof
In force
 · Low confidence
In forceLow confidence
US 8,754,098Forms of Rifaximin and Uses Thereof
In force
 · Low confidence
In forceLow confidence
US 9,034,892Forms of Rifaximin and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,273,066Forms of Rifaximin and Uses Thereof
In force
 · Low confidence
In forceLow confidence
US 9,546,183Forms of Rifaximin and Uses Thereof
In force
 · Low confidence
In forceLow confidence
US 9,700,545Forms of Rifaximin and Uses Thereof
In force
 · Low confidence
In forceLow confidence
10 of 50 patents shown.
Pro members see all 50.
Pro members: see all 50 patents
Also on record, not counted in the 50: 9 patents in force now held by others · 13 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 52 abandoned · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited